The US Senate has voted on
November 22 to open a full-fledged debate on President Barack
Obama’s most ambitious plan to overhaul the
nation’s healthcare system which will cost more than $1.2
trillion in the next 10 years.
The pharmaceutical industries
around the world can hope to
garner a significant chunk of the new spendings expected on providing
healthcare to additional 32 million uninsured Americans within a decade
There is good news for the global pharma industry. For the last three
decades many countries in Asia have prospered supplying a variety of
goods bought in large numbers by American consumers, who often
overextended themselves and went on shopping binges on credit.
Healthcare is also one of the prime movers of the US economy. At $2.5
trillion, it accounts for a sixth of the nation’s GDP. Most
Americans working in the industrial sector were provided expensive
health care through a combination of insurance policies
underwritten by their employers, covered only about half the citizens.
People who were outside the formal employment system have to buy
expensive insurance policies from insurance companies. Various studies
had estimated that over 50 million Americans did not have any insurance
cover. If the current system continued, experts expected at least 57
million Americans to remain uninsured by the year 2019.
Presidents from the Democratic Party had tried many times in the last
75 years to devise schemes which will be funded by the government to
enable millions of poor, uninsured citizens to get access to affordable
President Obama has come closer than any Democratic leader in the last
year to make their party’s major election plank a reality
within a year of assuming office.
The Democratic Party of President Obama crossed the first hurdle when
the country’s House of Representatives approved on November
27, a legislation sponsored by one of the party members.
America’s Affordable Health Choices Act of 2009 (H.R. 3962),
unveiled an $848 billion, 10-year plan to extend a government-supported
insurance scheme to enable millions of uninsured Americans to get the
benefits of modern health care.
About 25 million of these newly insured individuals would gain coverage
as a result of the expansion of Medicaid and the Children’s
Health Insurance Program (CHIP). Medicaid eligibility would be expanded
to include all legal residents with income under 150 percent of the
Federal Poverty Line (FPL).
A similar legislation has to be passed by the
country’s Upper House of Parliament, the Senate. Both the
Houses of Parliament will then resolve their differences in the
legislations passed by them which will then be sent to the President
for final approval.
On November 22, the Senate approved with majority votes (60-39) in a
100-member house, to start a full debate on the legislative changes
sought by Democrats to overhaul the $2.5 billion healthcare system.
This is not the last word. The Democratic Party’s proposals
will be debated intensively throughout December and by early January
2010, an appropriate legislation will go to the President for approval.
“Tonight we have the opportunity, the historic opportunity to
reform health care once and for all,” said Senator Max
Baucus, Democrat of Montana, and a chief architect of the legislation.
“History is knocking on the door. Let’s open it.
Let’s begin the debate.” Bacus was quoted saying
this by The New York Times, on the night of November 22 when the Senate
approved the proposal by a rare, voice vote.
“The healthcare debate is now officially under way on this
2,074 page, multi-trillion-dollar healthcare experiment,”
Republican Senate leader Mitch McConnell said. He said the final
Democratic holdouts had to “twist themselves into a
pretzel” to justify voting to move ahead on the Bill. Almost
all Senate Bills that clear the first hurdle eventually pass, he said.
The US government will have to find resources to fund the additional
expenses. Nearly $460 billion will be raised in the next 10 years
through additional taxes on individuals earning $500,000 a year and
couples $1 million. According to a report by the US Congressional
Office, US government intends to save more than $130 billion through
spending cuts and efficiency measures.
In addition, the government hopes to trim the expenses under the
current Medicare scheme by at least $400 billion in the next 10 years
so that these funds could be used to finance the new insurance schemes.
Some additional taxes on medical device makers is expected to net $20
The Republican Party has been strongly opposing the new measures. It
has quoted reports from the Centers for Medicare & Medicaid
Services (CMS), which has found that these deep cuts to Medicare would
likely result in real reductions in care, resulting in some hospitals
and nursing homes refusing Medicare patients altogether.
The Republican line is that hospitals will prefer to treat patients
with higher-paying private insurance policies. And so millions of
elderly Americans who possess the subsidized, affordable insurance
polices will be denied access or provided only substandard services as
hospitals tried to keep their costs within the budget.
Most experts agree that President Obama will have his way and the dream
plan to extend the benefits of medical insurance and medicare to
millions of more American will become a reality in 2010.
This will also have far reaching beneficial effects for the global
pharma industry. The US accounts for more than 40 percent of the global
pharma sales and the next biggest market (Japan) is one-tenth the size
of the US at just $ 60 billion.
The US government will push for steps that will lower the costs of
medicines and in such a strategy, generic medicines made in Asian
countries will get a big push.
The US market has been slow to accept the entry of conventional generic
medicines as well as biosimilar products of many biotech blockbuster
drugs. Over the next few years, the push to reduce US health care costs
could lead to a boom time for top quality, competitive generics pharma
companies in Asia.
In addition, more manufacturing may shift to Asia to keep costs down
and there will be more clinical trials of drugs besides drug discovery
work to keep the overall development costs down. Asia’s
quality drug makers can certainly look forward to better times.
Narayanan Suresh in Bangalore